SYNGENE: FY26 revenue up 3% YoY, but margins and PAT declined; ADC and biologics expanded
SYNGENE: FY26 revenue up 3% YoY, but margins and PAT declined; ADC and biologics expanded
SYNGENE: FY26 revenue up 3% YoY, but margins and PAT declined; ADC and biologics expanded
Sector
BROAD_MARKET
News Type
MARKET
Impact Level
MEDIUM
AI Sentiment
NEUTRAL
Published
04 May 2026
📎 Sources
Quartr | https://www.tradingview.com/news/urn:summary_document_slides:quartr.com:3273426:0-syngene-fy26-revenue-up-3-yoy-but-margins-and-pat-declined-adc-and-biologics-expanded/